SCHEDULE 13G/A: Macquarie Group Amends Passive Stake in Travere Therapeutics, Reports 4.9% Ownership

Macquarie Group Limited and its subsidiaries have filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2024.

Summary

• Macquarie Group Limited, along with its subsidiaries Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust, filed an Amendment No. 4 to Schedule 13G.
• The filing reports their beneficial ownership in Travere Therapeutics Inc. (CUSIP: 89422G107), a company with principal executive offices at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130.
• As of December 31, 2024, the aggregate amount beneficially owned by Macquarie Group Limited is 4,259,557 common shares.
• This represents 4.9% of the class of Travere Therapeutics Inc. common shares.
• Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each hold 4,259,557 shares with sole voting and sole dispositive power.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral in sentiment, as it is a factual disclosure of ownership. The slight decrease below 5% (implied by Amendment No. 4 and the 4.9% figure) could be seen as mildly negative, but it's a passive investment and likely a portfolio adjustment rather than a strong negative signal.

Positives

• Macquarie Group, a significant global financial institution, maintains a substantial passive investment in Travere Therapeutics, indicating continued, albeit slightly adjusted, confidence in the company's long-term prospects.
• The filing explicitly states the investment is for ordinary course of business and not for control, suggesting stability in the ownership structure and no immediate intent to influence management.

Negatives

• The reported ownership percentage of 4.9% is below the 5% threshold, which typically triggers initial 13G filings. This Amendment No. 4, showing a stake below 5%, suggests a reduction in holdings or a change in the total shares outstanding that brought them below the reporting threshold, which could be interpreted as a slight decrease in conviction or a portfolio rebalancing.

Future Outlook

The document is a Schedule 13G filing, which reports beneficial ownership and does not typically contain forward-looking statements or guidance from the issuer or the reporting entity regarding the issuer's future performance.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a passive investment by a major global financial services group in a biotechnology company. Such filings are routine for large asset managers and typically indicate portfolio allocation decisions rather than specific industry-wide trends, though the continued holding suggests a long-term view on the pharmaceutical or rare disease sector where Travere Therapeutics operates.

Comparison to Industry Standards

• This document is a regulatory filing detailing a passive ownership stake and does not provide performance metrics for comparison against industry standards or specific comparable companies or projects. It solely reports the beneficial ownership percentage of a specific investor.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming their continued, albeit slightly reduced, holding.
• Company Management: Awareness of a large, passive institutional holder, which typically implies less direct influence on corporate strategy compared to active investors.

Key Dates

Keywords

Travere Therapeutics Inc, Macquarie Group Limited, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing, Passive Investment